Synlogic Inc.

Company Overview

Business Model: SYNLOGIC, INC. was a biopharmaceutical company focused on rare metabolic disorders, developing novel therapeutics such as labafenogene marselecobac (SYNB1934) for phenylketonuria (PKU) and SYNB1353 for homocystinuria (HCU). In February 2024, the company discontinued its lead Phase 3 study (Synpheny-3 for SYNB1934) due to unlikelihood of meeting its primary endpoint, shifting its corporate strategy to pursuing strategic initiatives to enhance stockholder value, including a merger or sale of the Company. SYNLOGIC, INC. is currently a non-operating public shell company.

Market Position: Previously focused on addressing significant unmet needs in rare metabolic disorders. Following the discontinuation of its lead clinical program and substantial reduction in operations, SYNLOGIC, INC. is now a non-operating public shell company seeking a merger, acquisition, or other business combination. Its common stock was delisted from Nasdaq on January 21, 2026, and is now quoted on the OTC Markets Group, Inc. (OTC) under the symbol “SYBX.”

Recent Strategic Developments:

• February 2024: Discontinued Synpheny-3, the pivotal Phase 3 study of labafenogene marselecobac (SYNB1934) for PKU, based on an internal review indicating the trial was unlikely to meet its primary endpoint. The decision was not based on safety or tolerability concerns.
• February 2024: Initiated a corporate restructuring, substantially reducing operations and the workforce to one full-time employee.
• Ongoing: Actively pursuing strategic initiatives to enhance stockholder value, including the possibility of a merger or sale of the Company.
• January 2026: Delisted from The Nasdaq Capital Market and began trading on the OTC Markets Group, Inc. (OTC).

Geographic Footprint: Until June 26, 2024, SYNLOGIC, INC.'s corporate headquarters and operations were located in Cambridge, Massachusetts. The company's official address is now P.O. Box 30, Winchester, Massachusetts 01890. All equipment, leasehold improvements, and other fixed assets were physically located within the United States.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A (No revenue)
• Operating Margin: N/A (No revenue)
• Net Margin: N/A (No revenue)

Investment in Growth:

• R&D Expenditure: $0.04 million (2025) vs. $9.15 million (2024)
• Capital Expenditures: $0.0 million (2025) vs. $0.01 million (2024)
• Strategic Investments: Not applicable in the context of growth investment for a public shell. The company is focused on strategic alternatives for value enhancement.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: No repurchases of common stock during the quarter ended December 31, 2025. Treasury stock held at cost was $2.52 million (279,792 shares) as of December 31, 2025 and 2024.
• Dividend Payments: SYNLOGIC, INC. has never declared or paid any dividends to its stockholders since its inception.
• Dividend Yield: N/A
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $14.67 million (as of December 31, 2025)
• Total Debt: Current liabilities totaled $3.58 million as of December 31, 2025, primarily consisting of accounts payable ($0.10 million), accrued expenses ($0.92 million), and purchase warrant liability ($2.57 million). No long-term debt was disclosed.
• Net Cash Position: $11.09 million (Cash and Equivalents less Total Current Liabilities)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: Not disclosed.

Cash Flow Generation:

• Operating Cash Flow: $(4.36) million (2025) vs. $(31.66) million (2024)
• Free Cash Flow: $(4.36) million (2025) (Operating Cash Flow less Capital Expenditures of $0.0 million)
• Cash Conversion Metrics: Not disclosed.

Innovation & Technology Leadership

Research & Development Focus: SYNLOGIC, INC. discontinued its lead clinical program (labafenogene marselecobac/SYNB1934) in February 2024 and has no ongoing research and development activities. Previously, the focus was on developing Synthetic Biotics for rare metabolic disorders.

Core Technology Areas: Historically, SYNLOGIC, INC. focused on its Synthetic Biotic platform and disease-related technologies for conditions such as hyperphenylalaninemia, hyperoxaluria, homocystinuria, hyperuricemia, hyperammonemia, other inherited metabolic diseases, metabolic disorders, and inflammatory states.

Intellectual Property Portfolio:

• Patent Strategy: As of March 5, 2026, SYNLOGIC, INC. had over 114 Synlogic-owned patents and patent applications in U.S. and foreign jurisdictions, with over 63 issued or allowed. Patent terms for disease-related applications range from December 2035 to December 2043. The company relies on trade secrets, know-how, data exclusivity, market exclusivity, patent term extensions, and orphan drug designations.
• Licensing Programs: Not explicitly detailed as a current program for revenue generation or strategic partnerships.
• IP Litigation: The company may be involved in lawsuits to protect or enforce its patents or those of its licensors, or be subject to third-party infringement claims.

Technology Partnerships:

• Strategic Alliances: SYNLOGIC, INC. previously collaborated with Ginkgo Bioworks, Inc. for the research and development of engineered microbial therapeutic products but is no longer purchasing services from them.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: As of March 5, 2026, SYNLOGIC, INC. had one full-time employee, Mary Beth Dooley, primarily engaged in the assessment of strategic transactions.

Board Composition:

• Peter Barrett, Ph.D.: Chairman of the Board of Directors, Partner at Atlas Venture
• James Flynn: Managing Member and Portfolio Manager of Nerium Capital
• Edward Mathers: General Partner at New Enterprise Associates
• Richard P. Shea: Consulting CFO, Danforth Advisors

Human Capital Strategy

Workforce Composition:

• Total Employees: One full-time employee as of March 5, 2026.
• Skill Mix: The sole employee is primarily engaged in the assessment of strategic transactions.

Regulatory Environment & Compliance

Regulatory Framework:

• Industry-Specific Regulations: As a public shell company, SYNLOGIC, INC. is subject to SEC reporting requirements. Its securities were delisted from Nasdaq on January 21, 2026, and are now quoted on the OTC Markets Group, Inc. (OTC). State "blue sky" laws may restrict the resale of its securities.
• Legal Proceedings: SYNLOGIC, INC. is not currently a party to any material legal proceedings.

Internal Control Weakness: As of December 31, 2025, SYNLOGIC, INC. identified a material weakness in its internal control over financial reporting. This was due to an ineffective internal information and communication process related to significant and non-routine transactions, which resulted in misstatements of warrant liabilities, transaction costs, change in fair value of warrant liabilities, additional paid-in-capital, accumulated deficit, and related financial disclosures, requiring correction of prior financial statements. Remediation efforts are ongoing but have not yet been tested for effectiveness.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: 0% for the years ended December 31, 2025 and 2024.
• Tax Reform Impact: The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, includes permanent provisions for 100% bonus depreciation, immediate expensing of domestic research and development costs, and limitations on business interest expense deductibility. These provisions did not have a material impact on the effective income tax rate.

Net Operating Losses (NOLs): As of December 31, 2025, SYNLOGIC, INC. had federal net operating loss carryforwards of $401.8 million ($62.4 million expiring from 2034 to 2037, and $339.4 million with no expiration). State net operating loss carryforwards totaled $387.9 million, beginning to expire in 2029.

Tax Credit Carryforwards: As of December 31, 2025, the company had federal research and development tax credit carryforwards of $7.5 million and state research and development tax credit carryforwards of $4.4 million.

Section 382 Limitations: Utilization of NOLs and R&D credits may be subject to substantial annual limitation under Section 382 of the Internal Revenue Code due to past or future ownership changes. SYNLOGIC, INC. has not completed a study to assess these limitations.

Valuation Allowance: A full valuation allowance of $134.3 million (2025) and $134.4 million (2024) has been established against deferred tax assets due to the uncertainty of realizing these benefits from future taxable income.

Insurance & Risk Transfer

Risk Management Framework: SYNLOGIC, INC. carries information security risk insurance to provide protection against potential losses arising from cybersecurity incidents.